Ultrasound peripherals developer EchoCath has received Food and Drug Administration 510(k) clearance for EchoFlow, a blood-velocity measurement device that uses ultrasound to evaluate and quantify blood flow (SCAN 2/19/97). EchoFlow’s
Ultrasound peripherals developer EchoCath has received Food and Drug Administration 510(k) clearance for EchoFlow, a blood-velocity measurement device that uses ultrasound to evaluate and quantify blood flow (SCAN 2/19/97). EchoFlows applications include assessing the condition of blood vessels during and after surgery, determining proper placement of bypass grafts, and monitoring blood flow for implantable devices such as pacemakers, according to the Princeton, NJ-based firm. EchoCath will initially market EchoFlow to vascular surgeons for measuring blood-flow velocities but is also seeking corporate alliances for applications outside vascular surgery.
What a New Meta-Analysis Reveals About PET/CT Radiotracers for csPCa
February 6th 2025The PET/CT agent 18F-PSMA-1007 offered the highest surface under the cumulative ranking curve (SUCRA) out of nine radiotracers at the patient and lesion level for detecting clinically significant prostate cancer (csPCa), according to a meta-analysis.
New CT Angiography Study Shows Impact of COVID-19 on Coronary Inflammation and Plaque
February 5th 2025Prior COVID-19 infection was associated with a 28 percent higher progression of total percent atheroma volume (PAV) annually and over a 5 percent higher incidence of high-risk plaque in patients with coronary artery lesions, according to CCTA findings from a new study.